Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
BIL also holds an option to increase its equity stake by an additional 15%
Relonchem receives marketing authorization for Moxonidine tablets
Subscribe To Our Newsletter & Stay Updated
